JP2020517607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517607A5 JP2020517607A5 JP2019556587A JP2019556587A JP2020517607A5 JP 2020517607 A5 JP2020517607 A5 JP 2020517607A5 JP 2019556587 A JP2019556587 A JP 2019556587A JP 2019556587 A JP2019556587 A JP 2019556587A JP 2020517607 A5 JP2020517607 A5 JP 2020517607A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- compound according
- pharmaceutically acceptable
- solvates
- hydrates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C)C[C@]1N(C)C[C@@](c2cc(OC)c(*)cc2CC2)N2C1 Chemical compound CC(C)C[C@]1N(C)C[C@@](c2cc(OC)c(*)cc2CC2)N2C1 0.000 description 21
- LWGSSCJWIZDWSW-MJGOQNOKSA-N CC(C)C[C@H]1N(C)C[C@@H](c(c(CC2)c3)cc(OC)c3OCCCF)N2C1 Chemical compound CC(C)C[C@H]1N(C)C[C@@H](c(c(CC2)c3)cc(OC)c3OCCCF)N2C1 LWGSSCJWIZDWSW-MJGOQNOKSA-N 0.000 description 3
- HJTYCVBTCFTBKD-AEFFLSMTSA-N CC(C)C[C@H]1N(C)C[C@@H](c(c(CC2)c3)cc(OC)c3OCCF)N2C1 Chemical compound CC(C)C[C@H]1N(C)C[C@@H](c(c(CC2)c3)cc(OC)c3OCCF)N2C1 HJTYCVBTCFTBKD-AEFFLSMTSA-N 0.000 description 3
- QHZOEEKRHGYVCK-WHCXFUJUSA-N CN(C1)C(CC2CCC2)CN(CCc2c3)[C@H]1c2cc(OC)c3OCCF Chemical compound CN(C1)C(CC2CCC2)CN(CCc2c3)[C@H]1c2cc(OC)c3OCCF QHZOEEKRHGYVCK-WHCXFUJUSA-N 0.000 description 3
- KPDPDPZILQSFAV-UYAOXDASSA-N CN(C1)[C@H](CC2CCC2)CN(CC2)[C@H]1c(cc1OC)c2cc1OCCCF Chemical compound CN(C1)[C@H](CC2CCC2)CN(CC2)[C@H]1c(cc1OC)c2cc1OCCCF KPDPDPZILQSFAV-UYAOXDASSA-N 0.000 description 3
- YICWVSSLRZEOBI-SJLPKXTDSA-N CN(C1)[C@H](CC2CCC2)CN(CCc2c3)[C@H]1c2cc(OC)c3OCC(F)(F)F Chemical compound CN(C1)[C@H](CC2CCC2)CN(CCc2c3)[C@H]1c2cc(OC)c3OCC(F)(F)F YICWVSSLRZEOBI-SJLPKXTDSA-N 0.000 description 3
- BPRNLKLZWWRYQB-UHFFFAOYSA-N CC(C)(C)CC1N(C)CC(C)(c(c(CC2)c3)cc(OC)c3OC)N2C1 Chemical compound CC(C)(C)CC1N(C)CC(C)(c(c(CC2)c3)cc(OC)c3OC)N2C1 BPRNLKLZWWRYQB-UHFFFAOYSA-N 0.000 description 2
- LCICDLKGBXBEGT-ROPPNANJSA-N CC(C)(C)CC1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCCCC(F)(F)F)N2C1 Chemical compound CC(C)(C)CC1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCCCC(F)(F)F)N2C1 LCICDLKGBXBEGT-ROPPNANJSA-N 0.000 description 2
- IXIYNLWTQXWQQC-UHUGOGIASA-N CC(C)(C)CC1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCF)N2C1 Chemical compound CC(C)(C)CC1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCF)N2C1 IXIYNLWTQXWQQC-UHUGOGIASA-N 0.000 description 2
- FFQQPLXULFRCRI-WBVHZDCISA-N CC(C)(C)C[C@H]1N(C)C[C@@H](c(c(CC2)c3)cc(OC)c3OC)N2C1 Chemical compound CC(C)(C)C[C@H]1N(C)C[C@@H](c(c(CC2)c3)cc(OC)c3OC)N2C1 FFQQPLXULFRCRI-WBVHZDCISA-N 0.000 description 2
- SSVDACKPVANQIL-TZIWHRDSSA-N CC(C)(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCC3CCC3)N2C1 Chemical compound CC(C)(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCC3CCC3)N2C1 SSVDACKPVANQIL-TZIWHRDSSA-N 0.000 description 2
- QDPFPIMEAWOORE-DOGRWBMSSA-N CC(C)(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCC(C2)C2(F)F)N3C1 Chemical compound CC(C)(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCC(C2)C2(F)F)N3C1 QDPFPIMEAWOORE-DOGRWBMSSA-N 0.000 description 2
- LFJQSYSIACLOOE-NVXWUHKLSA-N CC(C)(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCC(F)(F)F)N3C1 Chemical compound CC(C)(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCC(F)(F)F)N3C1 LFJQSYSIACLOOE-NVXWUHKLSA-N 0.000 description 2
- UDELQOQFKFGXKY-UYAOXDASSA-N CC(C)(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCC2CC2)N3C1 Chemical compound CC(C)(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCC2CC2)N3C1 UDELQOQFKFGXKY-UYAOXDASSA-N 0.000 description 2
- IUXQTSFZTSAVFK-IEBWSBKVSA-N CC(C)(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCCOC)N3C1 Chemical compound CC(C)(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCCOC)N3C1 IUXQTSFZTSAVFK-IEBWSBKVSA-N 0.000 description 2
- JEAWDPVDKREOMR-WZONZLPQSA-N CC(C)(C)C[C@H]1N(C)C[C@](C)(c(c(CC2)c3)cc(OC)c3OCCCC(F)(F)F)N2C1 Chemical compound CC(C)(C)C[C@H]1N(C)C[C@](C)(c(c(CC2)c3)cc(OC)c3OCCCC(F)(F)F)N2C1 JEAWDPVDKREOMR-WZONZLPQSA-N 0.000 description 2
- LZPYOIPVIGUSJP-UHFFFAOYSA-N CC(C)CC1N(C)CC(C)(c(cc2OC)c(CC3)cc2OCC2CCC2)N3C1 Chemical compound CC(C)CC1N(C)CC(C)(c(cc2OC)c(CC3)cc2OCC2CCC2)N3C1 LZPYOIPVIGUSJP-UHFFFAOYSA-N 0.000 description 2
- UXYJUNGWIDYHOT-NNBQYGFHSA-N CC(C)CC1N(C)C[C@@H](c(cc2OC)c(CC3)cc2OC(C)C)N3C1 Chemical compound CC(C)CC1N(C)C[C@@H](c(cc2OC)c(CC3)cc2OC(C)C)N3C1 UXYJUNGWIDYHOT-NNBQYGFHSA-N 0.000 description 2
- ICIKYPUVZPRHMT-ROPPNANJSA-N CC(C)CC1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCCC#N)N2C1 Chemical compound CC(C)CC1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCCC#N)N2C1 ICIKYPUVZPRHMT-ROPPNANJSA-N 0.000 description 2
- XCJFEGSDQRERME-ROPPNANJSA-N CC(C)CC1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCCCF)N2C1 Chemical compound CC(C)CC1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCCCF)N2C1 XCJFEGSDQRERME-ROPPNANJSA-N 0.000 description 2
- HJTYCVBTCFTBKD-UHUGOGIASA-N CC(C)CC1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCF)N2C1 Chemical compound CC(C)CC1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCF)N2C1 HJTYCVBTCFTBKD-UHUGOGIASA-N 0.000 description 2
- FJECVIKULOKQEK-IJHRGXPZSA-N CC(C)CC1N(CC(C)C)C[C@@H](c(c(CC2)c3)cc(OC)c3OC)N2C1 Chemical compound CC(C)CC1N(CC(C)C)C[C@@H](c(c(CC2)c3)cc(OC)c3OC)N2C1 FJECVIKULOKQEK-IJHRGXPZSA-N 0.000 description 2
- KFNOWWDGJKOLHK-WBVHZDCISA-N CC(C)C[C@H]1N(C)C[C@@H](c(cc2OC)c(CC3)cc2OC)N3C1 Chemical compound CC(C)C[C@H]1N(C)C[C@@H](c(cc2OC)c(CC3)cc2OC)N3C1 KFNOWWDGJKOLHK-WBVHZDCISA-N 0.000 description 2
- XTVKTAYLFFSQAV-YLJYHZDGSA-N CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OC3CCC3)N2C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OC3CCC3)N2C1 XTVKTAYLFFSQAV-YLJYHZDGSA-N 0.000 description 2
- SDKSOKMAAYDNNM-UYAOXDASSA-N CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCC(C)C)N2C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCC(C)C)N2C1 SDKSOKMAAYDNNM-UYAOXDASSA-N 0.000 description 2
- VTAOPLYMQRUKAD-SJLPKXTDSA-N CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCC(F)(F)F)N2C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCC(F)(F)F)N2C1 VTAOPLYMQRUKAD-SJLPKXTDSA-N 0.000 description 2
- LWGSSCJWIZDWSW-IEBWSBKVSA-N CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCCF)N2C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCCF)N2C1 LWGSSCJWIZDWSW-IEBWSBKVSA-N 0.000 description 2
- BSQPEKSYIOWAPF-IEBWSBKVSA-N CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCOC)N2C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCOC)N2C1 BSQPEKSYIOWAPF-IEBWSBKVSA-N 0.000 description 2
- XZHVZWDYSQVFGO-VQIMIIECSA-N CC(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OC2CC2)N3C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OC2CC2)N3C1 XZHVZWDYSQVFGO-VQIMIIECSA-N 0.000 description 2
- DVFSEMKAYDMVAP-DOGRWBMSSA-N CC(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCC(C2)C2(F)F)N3C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCC(C2)C2(F)F)N3C1 DVFSEMKAYDMVAP-DOGRWBMSSA-N 0.000 description 2
- XSJZLZFCSPLOGV-IEBWSBKVSA-N CC(C)Oc1cc(CCN2[C@@H]3CN(C)[C@H](CC(C)(C)C)C2)c3cc1OC Chemical compound CC(C)Oc1cc(CCN2[C@@H]3CN(C)[C@H](CC(C)(C)C)C2)c3cc1OC XSJZLZFCSPLOGV-IEBWSBKVSA-N 0.000 description 2
- SRJAEVUCPGPMFO-CGHJUBPDSA-N CC1(c(c(CC2)c3)cc(OC)c3OCCCCF)N2C[C@@H](CC2CCC2)N(C)C1 Chemical compound CC1(c(c(CC2)c3)cc(OC)c3OCCCCF)N2C[C@@H](CC2CCC2)N(C)C1 SRJAEVUCPGPMFO-CGHJUBPDSA-N 0.000 description 2
- JZGWRAFARFGJHC-IEBWSBKVSA-N CCCOc1cc(CCN2[C@@H]3CN(C)[C@H](CC(C)C)C2)c3cc1OC Chemical compound CCCOc1cc(CCN2[C@@H]3CN(C)[C@H](CC(C)C)C2)c3cc1OC JZGWRAFARFGJHC-IEBWSBKVSA-N 0.000 description 2
- QLFARQMEWFMXOG-GOSISDBHSA-N CCN(C)[C@H](CC(C)C)CN(CCc1c2)Cc1cc(OC)c2OCC(F)(F)F Chemical compound CCN(C)[C@H](CC(C)C)CN(CCc1c2)Cc1cc(OC)c2OCC(F)(F)F QLFARQMEWFMXOG-GOSISDBHSA-N 0.000 description 2
- COWHXWAJCAPRBE-UHUGOGIASA-N CCN(C1)C(CC(C)C)CN(CCc2c3)[C@H]1c2cc(OC)c3OC Chemical compound CCN(C1)C(CC(C)C)CN(CCc2c3)[C@H]1c2cc(OC)c3OC COWHXWAJCAPRBE-UHUGOGIASA-N 0.000 description 2
- COWHXWAJCAPRBE-AEFFLSMTSA-N CCN(C1)[C@H](CC(C)C)CN(CCc2c3)[C@@H]1c2cc(OC)c3OC Chemical compound CCN(C1)[C@H](CC(C)C)CN(CCc2c3)[C@@H]1c2cc(OC)c3OC COWHXWAJCAPRBE-AEFFLSMTSA-N 0.000 description 2
- YNXYNRFUMLCJMA-PYUWXLGESA-N CCOc1cc(CCN2C3CN(C)[C@H](CC(C)(C)C)C2)c3cc1OC Chemical compound CCOc1cc(CCN2C3CN(C)[C@H](CC(C)(C)C)C2)c3cc1OC YNXYNRFUMLCJMA-PYUWXLGESA-N 0.000 description 2
- IUIMAMMQZMWWKJ-SJLPKXTDSA-N CCOc1cc(CCN2[C@@H]3CN(C)[C@H](CC(C)C)C2)c3cc1OC Chemical compound CCOc1cc(CCN2[C@@H]3CN(C)[C@H](CC(C)C)C2)c3cc1OC IUIMAMMQZMWWKJ-SJLPKXTDSA-N 0.000 description 2
- KPDPDPZILQSFAV-IJHRGXPZSA-N CN(C1)C(CC2CCC2)CN(CCc2c3)[C@@H]1c2cc(OC)c3OCCCF Chemical compound CN(C1)C(CC2CCC2)CN(CCc2c3)[C@@H]1c2cc(OC)c3OCCCF KPDPDPZILQSFAV-IJHRGXPZSA-N 0.000 description 2
- WZENSGDMRUIJSD-TZIWHRDSSA-N CN(C1)[C@H](CC2CCC2)CN(CCc2c3)[C@H]1c2cc(OC)c3OCC1CC1 Chemical compound CN(C1)[C@H](CC2CCC2)CN(CCc2c3)[C@H]1c2cc(OC)c3OCC1CC1 WZENSGDMRUIJSD-TZIWHRDSSA-N 0.000 description 2
- NNJRHTJYBQWIMI-DLCOBIQGSA-N C[C@@]1(c(cc2OC)c(CC3)cc2OCC(C2)C2(F)F)N3C[C@@H](CC2CCC2)N(C)C1 Chemical compound C[C@@]1(c(cc2OC)c(CC3)cc2OCC(C2)C2(F)F)N3C[C@@H](CC2CCC2)N(C)C1 NNJRHTJYBQWIMI-DLCOBIQGSA-N 0.000 description 2
- AWFDVMQONFPYRJ-IWPPFLRJSA-N CC(C)(C)C[C@H]1N(C)CC(C)(c(cc2OC)c(CC3)cc2OI)N3C1 Chemical compound CC(C)(C)C[C@H]1N(C)CC(C)(c(cc2OC)c(CC3)cc2OI)N3C1 AWFDVMQONFPYRJ-IWPPFLRJSA-N 0.000 description 1
- PKJORHGVWPMFQN-UHFFFAOYSA-N CC(C)CC1N(C)CC(c(c(CC2)c3)cc(OC)c3OCC3CCC3)N2C1 Chemical compound CC(C)CC1N(C)CC(c(c(CC2)c3)cc(OC)c3OCC3CCC3)N2C1 PKJORHGVWPMFQN-UHFFFAOYSA-N 0.000 description 1
- BSQPEKSYIOWAPF-WHCXFUJUSA-N CC(C)CC1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCOC)N2C1 Chemical compound CC(C)CC1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCOC)N2C1 BSQPEKSYIOWAPF-WHCXFUJUSA-N 0.000 description 1
- LEKAICKPZLBWPT-HWYAHNCWSA-N CC(C)C[C@H]1N(C)CC(C)(c(c(CC2)c3)cc(OC)c3OCC(C)C)N2C1 Chemical compound CC(C)C[C@H]1N(C)CC(C)(c(c(CC2)c3)cc(OC)c3OCC(C)C)N2C1 LEKAICKPZLBWPT-HWYAHNCWSA-N 0.000 description 1
- UXYJUNGWIDYHOT-MJGOQNOKSA-N CC(C)C[C@H]1N(C)C[C@@H](c(cc2OC)c(CC3)cc2OC(C)C)N3C1 Chemical compound CC(C)C[C@H]1N(C)C[C@@H](c(cc2OC)c(CC3)cc2OC(C)C)N3C1 UXYJUNGWIDYHOT-MJGOQNOKSA-N 0.000 description 1
- IIQOFVCOVDRFOW-IEBWSBKVSA-N CC(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCC=C)N3C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCC=C)N3C1 IIQOFVCOVDRFOW-IEBWSBKVSA-N 0.000 description 1
- HJTYCVBTCFTBKD-SJLPKXTDSA-N CC(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCCF)N3C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCCF)N3C1 HJTYCVBTCFTBKD-SJLPKXTDSA-N 0.000 description 1
- IBPFEDHRQVUITA-VGOFRKELSA-N CC(C)C[C@H]1N(C)C[C@](C)(c(cc2OC)c(CC3)cc2OC2CC2)N3C1 Chemical compound CC(C)C[C@H]1N(C)C[C@](C)(c(cc2OC)c(CC3)cc2OC2CC2)N3C1 IBPFEDHRQVUITA-VGOFRKELSA-N 0.000 description 1
- JZGWRAFARFGJHC-DUSLRRAJSA-N CCCOc(cc(CCN1C2CN(C)[C@H](CC(C)C)C1)c2c1)c1OC Chemical compound CCCOc(cc(CCN1C2CN(C)[C@H](CC(C)C)C1)c2c1)c1OC JZGWRAFARFGJHC-DUSLRRAJSA-N 0.000 description 1
- XUQXNDPCVFIZEE-AFMYVXGZSA-N CN(C1)C(CC2CCC2)CN(CCc2c3)[C@H]1c2cc(OC)c3OCC(C1)C1(F)F Chemical compound CN(C1)C(CC2CCC2)CN(CCc2c3)[C@H]1c2cc(OC)c3OCC(C1)C1(F)F XUQXNDPCVFIZEE-AFMYVXGZSA-N 0.000 description 1
- UJCUCMSCZHKGHA-OMOCHNIRSA-N CN(C1)C(CC2CCC2)CN(CCc2c3)[C@H]1c2cc(OC)c3OI Chemical compound CN(C1)C(CC2CCC2)CN(CCc2c3)[C@H]1c2cc(OC)c3OI UJCUCMSCZHKGHA-OMOCHNIRSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487413P | 2017-04-19 | 2017-04-19 | |
| US62/487,413 | 2017-04-19 | ||
| US201862652837P | 2018-04-04 | 2018-04-04 | |
| US62/652,837 | 2018-04-04 | ||
| PCT/US2018/028031 WO2018195121A1 (en) | 2017-04-19 | 2018-04-17 | Vmat2 inhibitor compounds and compositions thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517607A JP2020517607A (ja) | 2020-06-18 |
| JP2020517607A5 true JP2020517607A5 (enExample) | 2021-05-27 |
| JP7170662B2 JP7170662B2 (ja) | 2022-11-14 |
Family
ID=62111264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556587A Active JP7170662B2 (ja) | 2017-04-19 | 2018-04-17 | Ｖｍａｔ２インヒビター化合物およびその組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11040970B2 (enExample) |
| EP (1) | EP3612532B1 (enExample) |
| JP (1) | JP7170662B2 (enExample) |
| KR (1) | KR20190140968A (enExample) |
| CN (1) | CN110770236B (enExample) |
| AU (1) | AU2018254429A1 (enExample) |
| BR (1) | BR112019021853A2 (enExample) |
| CA (1) | CA3060251A1 (enExample) |
| CL (1) | CL2019002919A1 (enExample) |
| CO (1) | CO2019011604A2 (enExample) |
| ES (1) | ES2971230T3 (enExample) |
| JO (1) | JOP20190239A1 (enExample) |
| MA (1) | MA50145A (enExample) |
| MX (1) | MX2019012336A (enExample) |
| PE (1) | PE20191784A1 (enExample) |
| TW (1) | TW201841913A (enExample) |
| WO (1) | WO2018195121A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY203491A (en) | 2017-01-27 | 2024-06-30 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| PL3684333T3 (pl) | 2017-09-21 | 2025-06-23 | Neurocrine Biosciences, Inc. | Formulacja walbenazyny o wysokiej dawce oraz kompozycje, sposoby i zestawy z nią związane |
| KR20250110361A (ko) | 2017-10-10 | 2025-07-18 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| MX2020013004A (es) * | 2018-06-14 | 2021-02-17 | Neurocrine Biosciences Inc | Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. |
| MX2021001017A (es) | 2018-08-15 | 2021-04-19 | Neurocrine Biosciences Inc | Metodos para la administracion de ciertos inhibidores de transportador vesicular de monoamina de proteinas transportadoras-2 (vmat2). |
| TW202033521A (zh) * | 2018-10-24 | 2020-09-16 | 美商紐羅克里生物科學有限公司 | 製備囊泡單胺轉運蛋白2(vmat2)抑制劑之方法 |
| AR120109A1 (es) | 2019-09-30 | 2022-02-02 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores |
| IL292524A (en) | 2019-11-11 | 2022-06-01 | Incyte Corp | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| RS67052B1 (sr) | 2021-03-22 | 2025-08-29 | Neurocrine Biosciences Inc | Vmat2 inhibitori i postupci primene |
| WO2022232380A1 (en) | 2021-04-29 | 2022-11-03 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
| US20250064990A1 (en) | 2021-08-20 | 2025-02-27 | Neurocrine Biosciences, Inc. | Methods of screening for vmat2 inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| GB0106177D0 (en) | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| ES2327740T3 (es) | 2003-06-20 | 2009-11-03 | F. Hoffmann-La Roche Ag | Hexahidropiridoisoquinolinas como inhibidoras de la dpp-iv. |
| JP2008509925A (ja) * | 2004-08-13 | 2008-04-03 | オメロス コーポレイション | 新規のセロトニンレセプターリガンドおよびそれらの使用 |
| BRPI0718247B1 (pt) | 2006-11-08 | 2021-09-21 | Neurocrine Biosciences, Inc. | Composto usado como inibidor do transportador de monoamina vesicular 2, composição farmacêutica compreendendo o dito composto e uso da dita composição farmacêutica no tratamento de transtornos hipercinéticos |
| FR2912145B1 (fr) | 2007-02-02 | 2009-03-06 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2009126305A1 (en) * | 2008-04-11 | 2009-10-15 | The Trustees Of Columbia University | Glucose metabolism modulating compounds |
| LT3061760T (lt) | 2008-09-18 | 2018-02-26 | Auspex Pharmaceuticals, Inc. | Deuterinti benzochinolizino dariniai kaip vezikuliarinio monoamino transporterio 2 slopikliai |
| US8772301B2 (en) * | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| CN102285984B (zh) * | 2010-11-25 | 2012-10-10 | 江苏威凯尔医药科技有限公司 | (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法 |
| WO2014043866A1 (zh) | 2012-09-19 | 2014-03-27 | 中国科学院福建物质结构研究所 | 噻吩[2,3-d]嘧啶衍生物、其制备方法及其用途 |
| US9782398B2 (en) | 2014-02-07 | 2017-10-10 | Neurocrine Biosciences, Inc. | Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof |
| WO2016127133A1 (en) | 2015-02-06 | 2016-08-11 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| MY197501A (en) | 2016-12-22 | 2023-06-19 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| KR102696516B1 (ko) | 2016-12-22 | 2024-08-22 | 인사이트 코포레이션 | 면역조절제로서의 벤조옥사졸 유도체 |
-
2017
- 2017-06-16 JO JOP/2019/0239A patent/JOP20190239A1/ar unknown
-
2018
- 2018-04-17 TW TW107112964A patent/TW201841913A/zh unknown
- 2018-04-17 PE PE2019002077A patent/PE20191784A1/es unknown
- 2018-04-17 MX MX2019012336A patent/MX2019012336A/es unknown
- 2018-04-17 JP JP2019556587A patent/JP7170662B2/ja active Active
- 2018-04-17 CN CN201880040884.XA patent/CN110770236B/zh active Active
- 2018-04-17 US US16/606,191 patent/US11040970B2/en active Active
- 2018-04-17 CA CA3060251A patent/CA3060251A1/en active Pending
- 2018-04-17 BR BR112019021853-0A patent/BR112019021853A2/pt not_active Application Discontinuation
- 2018-04-17 AU AU2018254429A patent/AU2018254429A1/en not_active Abandoned
- 2018-04-17 WO PCT/US2018/028031 patent/WO2018195121A1/en not_active Ceased
- 2018-04-17 KR KR1020197033620A patent/KR20190140968A/ko not_active Withdrawn
- 2018-04-17 ES ES18722357T patent/ES2971230T3/es active Active
- 2018-04-17 MA MA050145A patent/MA50145A/fr unknown
- 2018-04-17 EP EP18722357.3A patent/EP3612532B1/en active Active
-
2019
- 2019-10-14 CL CL2019002919A patent/CL2019002919A1/es unknown
- 2019-10-18 CO CO2019011604A patent/CO2019011604A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517607A5 (enExample) | ||
| ES2973442T3 (es) | Moduladores de la vía integrada del estrés | |
| JP6657182B2 (ja) | 癌治療用のｃｄ７３阻害剤としてのプリン誘導体 | |
| JP2010138190A5 (enExample) | ||
| TWI500616B (zh) | 新穎之雙環吡啶酮 | |
| JP2011529918A5 (enExample) | ||
| JP2009538910A5 (enExample) | ||
| JP2011530521A5 (enExample) | ||
| RU2007119585A (ru) | Производные рапамицина и их применение при лечении неврологических заболеваний | |
| JP2019518766A5 (enExample) | ||
| CN1706813A (zh) | 含长链脂肪酰基取代的文拉法辛前体药物及其制备方法和用途 | |
| JP2014526469A5 (enExample) | ||
| JP2017531020A5 (enExample) | ||
| JP2004534816A5 (enExample) | ||
| CA2339008A1 (en) | Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases | |
| JP2019535825A5 (enExample) | ||
| JP2013505946A5 (enExample) | ||
| JP2007508361A5 (enExample) | ||
| JP2009527462A5 (enExample) | ||
| JP2011517443A5 (enExample) | ||
| JP2022153568A (ja) | 化合物、組成物および方法 | |
| JP2017508736A (ja) | びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤 | |
| JP2011525185A5 (enExample) | ||
| RU2019110048A (ru) | Твердые формы валбеназина | |
| CN108884124A (zh) | 碳硼烷化合物及其使用方法 |